Literature DB >> 8886177

Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney.

H Rabb1, E Barroso-Vicens, R Adams, J Pow-Sang, G Ramirez.   

Abstract

Integrins are transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions. Altered integrin expression may contribute to tumor progression, invasiveness and metastases. The alpha-V/beta-3 (alpha v beta 3; osteopontin/ vitronectin receptor) has recently been implicated in neovascularization and tumor-induced angiogenesis. alpha v-Subunit also associates with beta 5 to form an alpha v beta 5-complex, another vitronectin receptor. We studied tissue distribution of alpha v beta 3-and alpha v beta 5-integrins, as well as alpha 1- and beta 1-subunits in nephrectomy samples from 7 subjects with localized renal cell carcinoma. Grossly and histologically uninvolved regions ('normal') from the same nephrectomy specimens were used for comparison. Integrin expression was studied with specific monoclonal antibodies and the immunoperoxidase technique. alpha v beta 3 was expressed in the glomerular epithelial cells, Bowman's capsule, vascular endothelium, and weakly in tubular epithelial cells. alpha v beta 5 had a similar distribution except for minimal expression on vascular endothelium. alpha 1-Expression was observed in mesangium and but weakly in Bowman's capsule. beta 1-Expression was seen in glomerular epithelial cells, Bowman's capsule, vascular epithelium and tubular epithelial cells. Unlike in 'normals', neoplastic expression was more heterogeneous alpha v beta 3 was expressed in tumor cells in 4/7 cases, vascular endothelium in 6/6, and in stroma in 4/7. alpha v beta 5 was weakly expressed in tumor cells in 4/5, vascular endothelium in 5/5, and stroma in 4/5 cases. alpha 1-Expression was seen in tumor cells in 3/7, vascular endothelium in 4/7 and in stroma in 7/7 cases. beta 1-Expression was seen in tumor cells in 7/7 cases, vascular endothelium in 7/7, and in stroma in 4/7 cases. This study delineates the pattern of expression of the alpha v beta 3-and alpha v beta 5-integrins in 'normal' and neoplastic human kidney. Variations in alpha v beta 3-and alpha v beta 5-integrin expression may play a role in normal and neoplastic processes of the kidney.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886177     DOI: 10.1159/000169032

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

Review 1.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

2.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

Review 3.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

4.  Comparing the expression of integrins αvβ3, αvβ5, αvβ6, αvβ8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors.

Authors:  Jens Schittenhelm; Annemarie Klein; Marcos S Tatagiba; Richard Meyermann; Falko Fend; Simon L Goodman; Bence Sipos
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

5.  Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study.

Authors:  Yurong Cheng; Yong Li; Nora Scherer; Franziska Grundner-Culemann; Terho Lehtimäki; Binisha H Mishra; Olli T Raitakari; Matthias Nauck; Kai-Uwe Eckardt; Peggy Sekula; Ulla T Schultheiss
Journal:  PLoS Genet       Date:  2022-04-06       Impact factor: 5.917

6.  Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.

Authors:  E Passalidou; M Trivella; N Singh; M Ferguson; J Hu; A Cesario; P Granone; A G Nicholson; P Goldstraw; C Ratcliffe; M Tetlow; I Leigh; A L Harris; K C Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

7.  An immunofluorescence assay for extracellular matrix components highlights the role of epithelial cells in producing a stable, fibrillar extracellular matrix.

Authors:  Omar S Qureshi; Hélène Bon; Breda Twomey; Gill Holdsworth; Kirsty Ford; Marianne Bergin; Linghong Huang; Mariusz Muzylak; Louise J Healy; Vanessa Hurdowar; Timothy S Johnson
Journal:  Biol Open       Date:  2017-10-15       Impact factor: 2.422

8.  Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma.

Authors:  E Passalidou; M Stewart; M Trivella; G Steers; G Pillai; A Dogan; I Leigh; C Hatton; A Harris; K Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.